Effect of Remote Symptom Monitoring Using a Mobile App on Weight Loss and Survival in Patients Receiving Radiotherapy or Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating the impact of remote symptom monitoring on patients with Head and Neck Squamous Cell Carcinoma HNSCC who are receiving curative radiotherapy or chemoradiotherapy. The study aims to see if digital tools can help detect problems early and reduce the proportion of patients experiencing at least 5% weight loss within three months after treatment. This approach may help improve care by addressing symptoms before they worsen. Participants will be randomly assigned to one of two groups. One group receives standard care without additional monitoring. The other group uses Resilience PRO, a mobile phone app that regularly asks about symptoms and sends alerts to the care team when important issues arise. This allows timely adjustments to treatment and support. The study will continue to monitor survival at 12 and 18 months after treatment. Throughout the study, participants will be followed for symptom reporting, weight changes, and survival outcomes. The research team will collect data via the app and standard clinical visits. The main measure is the impact of remote monitoring on weight loss three months after treatment. Secondary measures include survival rates up to 18 months. The total participation period extends at least 18 months with ongoing evaluation of health status and treatment effects.

Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)